Total raised in public, private and other financings of biopharma companies, comparing 2019-2025.

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharma deals October 2025

Biopharma dealmaking activity remained strong in October, with total deal value reaching 31ドル.86 billion, a 17% increase from 27ドル.15 billion in September and ranking as the second-highest month in 2025 after June’s 35ドル.43 billion.

Index insights

Biopharma companies focused on infectious disease extended their stock recoveries through the third quarter (Q3), with the BioWorld Infectious Disease Index closing October up 28.98%. The gain marks a strong turnaround from earlier in the year, when the index had fallen 17.83% by the end of April before rebounding to a 4.34% gain by July’s close.

Korro Bio Inc.’s latest update on RNA editing prospect KRRO-110 may mean one less competitor in alpha-1 antitrypsin deficiency (AATD), and shares of the firm (NASDAQ:KRRO) closed Nov. 13 at 6ドル.50, down 24ドル.92, or 79%. As part of the third-quarter earnings report, Korro said KRRO-110 produced functional protein in AATD patients but fell short of projected levels of functional protein after a single administration.

A year ago, BioWorld published a special series on the women’s health drug development ecosystem, showing that while women make up half of the population, venture capital investment and life sciences partnerships in the space – specifically those deals supporting innovations for conditions primarily affecting women – pale in comparison to efforts addressing diseases more men experience. That appears to be changing, according to an updated look of BioWorld data, supported by findings in the Silicon Valley Bank 2025 Innovation in Women’s Health Report published in April, and Clarivate’s Nov. 13 release of its latest Companies to Watch 2025 report, Rediscovering women’s health.

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to 2ドル.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ABL will receive a 40ドル million up-front payment and up to 2ドル.56 billion in development, regulatory and commercialization milestones, plus tiered royalties on net sales.

At the busy annual congress of the American College of Surgeons in Chicago, attendees heard about a study that found rectal bleeding in younger adults – those under 50 years of age – increased their odds of a colorectal cancer (CRC) diagnosis by a shocking 850%. Already, the demographic has turned up sharply higher cases of the disease in recent years. The ACS meeting was held Oct. 4-7.

Drug developer stocks strengthened further through September and October, with the BioWorld Drug Developers Index (BDDI) rising from a 7.69% gain at the end of August, to 24.91% through the third quarter and 28.96% at October’s close. The BDDI outperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which finished October up 24.49% and 11.8%, respectively.

The top 10 biopharma stock gainers and losers for the week.